MedTrace Logo

Symptom Screening Linked to Care Pathways

NCT04614662 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 445

Last updated 2025-09-23

Study results available
· View outcomes & findings →

Summary

Most children with cancer survive because they are given intensive treatments, but unfortunately, these treatments are associated with distressing symptoms. To address this problem, we developed the Symptom Screening in Pediatrics Tool (SSPedi) so that children receiving cancer treatments can communicate their bothersome symptoms, and Supportive care Prioritization, Assessment and Recommendations for Kids (SPARK), a web-based application that links identified symptoms to supportive care guidelines for symptom management. To establish that these tools improve the lives of children newly diagnosed with cancer, we will conduct a trial that randomizes 20 pediatric cancer institutions and measures the impact of three times weekly symptom screening, symptom feedback to healthcare providers and the development of care pathways for symptom management to improve total symptom burden, fatigue and quality of life.

Conditions

  • Pediatric Cancer
  • Quality of Life

Interventions

BEHAVIORAL

SPARK Symptom Screening Linked to Feedback to Providers

Symptom screening three times weekly via SPARK, feedback of symptoms to healthcare providers and development of care pathways for symptom management.

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • The Hospital for Sick Children

    lead OTHER

Principal Investigators

  • Lillian Sung, MD, PhD · The Hospital for Sick Children

  • Laura Lee Dupuis, RPh, PhD · The Hospital for Sick Children

  • Allison Grimes, MD · The University of Texas Health Science Center at San Antonio

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
8 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-02
Primary Completion
2023-10-18
Completion
2023-10-25

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04614662 on ClinicalTrials.gov